ReviewBritish journal of haematology2017
Knowledge insufficient: the management of haemoglobin SC disease.
Review in British journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- EHA Guidelines on the management of children and adults with hemoglobin SC disease.HemaSphere · 2026Article
- Cerebral fat embolism syndrome in sickle cell disease: a case highlighting the predominance of susceptibility-weighted imaging findings and literature review.Radiology case reports · 2026Article
- Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence-guided care.British journal of haematology · 2026Article
- Enhancing missense variant classification in predicted intrinsically disordered regions.PloS one · 2026Article
- Association Between Haemoglobin Variant Phenotypes and Red Blood Cell Parameters Among Pregnant Women: A Hospital-Based Cross-Sectional Study in Ghana.BioMed research international · 2026Article
- A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies.Blood advances · 2025Article
- Can platelet to neutrophil ratio (PNR) serve as a viable alternative tool for monitoring sickle cell disease patients on hydroxyurea in low income countries?Annals of hematology · 2025Article
- Article
- Article
- Sickle cell retinopathy among Ghanaian high school students: a school-based screening.BMJ global health · 2024Article
- Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.Expert review of hematology · 2024Review
- Constitutive hypercoagulability in pediatric sickle cell disease patients with hemoglobin SS genotype.Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Most adults with severe HbSC disease are not treated with hydroxyurea.Blood advances · 2023Article
- It's high time to turn the spotlight on HbSC disease.Blood advances · 2023Article
- Go the Distance: Reproductive Health Care for People with Sickle Cell Disease.Hematology/oncology clinics of North America · 2022Review
- Anemia in the pediatric patient.Blood · 2022Article
- Unrecognized hemoglobin SC sickle cell disease complicated by sepsis and cholestasis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Liver Transplant in Hemoglobin SC Disease and Autoimmune Hepatitis: A Case Report.Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2022Article
- A Patient With Hemoglobin SC Disease and Acute Ischemic Stroke Presenting With Altered Mental Status.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Although haemoglobin SC (HbSC) accounts for 30% of sickle cell disease (SCD) in the United States and United Kingdom, evidence-based guidelines for genotype specific management are lacking. The unique pathology of HbSC disease is complex, characterized by erythrocyte dehydration, intracellular sickling and increased blood viscosity. The evaluation and treatment of patients with HbSC is largely inferred from studies of SCD consisting mostly of haemoglobin SS (HbSS) patients. These studies are underpowered to allow definitive conclusions about HbSC. We review the pathophysiology of HbSC disease, including known and potential differences between HbSS and HbSC, and highlight knowledge gaps in HbSC disease management. Clinical and translational research is needed to develop targeted treatments and to validate management recommendations for efficacy, safety and impact on quality of life for people with HbSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.